SCHEMBL434805

SCHEMBL434805

CCOC(=O)c1cc(C)on1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
ALDH1A1 P00352 2/20 0.55
ESR1 P03372 1/20 0.55
POLB P06746 1/20 0.55
HPGD P15428 1/20 0.55
ALOX12 P18054 1/20 0.55
PPARG P37231 1/20 0.55
NCOA2 Q15596 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
MAPT P10636 6/20 0.55
TP53 P04637 2/20 0.55
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
CYP1A2 P05177 2/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190095 0.90 MEN1 (0.52) MEN1KMT2AALDH1A1ESR1POLB
SCHEMBL6966443 0.85 ALDH1A1 (0.52) MEN1KMT2AALDH1A1ESR1POLB
SCHEMBL19407110 0.85 CYP1A2 (0.49) MEN1KMT2AALDH1A1ESR1POLB
SCHEMBL162619 0.83 CYP1A2 (0.50) MEN1KMT2AALDH1A1POLBMAPT
SCHEMBL31286841 0.83 CYP1A2 (0.50) MEN1KMT2AALDH1A1ESR1MAPT
SCHEMBL15640906 0.81 CYP1A2 (0.49) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL4478920 0.81 CYP1A2 (0.49) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL21523835 0.81 ALDH1A1 (0.49) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL892581 0.81 MAPT (0.50) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL12416443 0.81 CYP1A2 (0.49) MEN1KMT2AALDH1A1ESR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 US disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 EP disclosed
CN-114466849-B N-substituted-3, 4- (fused 5-ring) -5-phenyl-pyrrolidin-2-one compounds as ISOQC and/or inhibitors of QC enzymes 欣尼克免疫有限公司 2024-07-12 CN disclosed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 CN disclosed
US-11958854-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2024-04-16 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 EP disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 WO disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 WO disclosed
EP-0150984-B1 6-(SUBSTITUTED) METHYLENEPENICILLANIC AND 6-(SUBSTITUTED) HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF PFIZER INC. (US) 1991-09-11 EP disclosed
US-5041567-A Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis BEECHAM GROUP PLC (GB) 1991-08-20 US disclosed
US-5015473-A Beta-lactamase inhibitors PFIZER INC. (US) 1991-05-14 US disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 EP disclosed
US-4853027-A PREEMGENCE, POSTEMERGENCE HOERBICIDES; WEEDS, GRASSES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-08-01 US disclosed
US-4826833-A ANTIBIOTICS PFIZER INC. (US) 1989-05-02 US disclosed
US-4812470-A Antibacterial monic acid derivatives BEECHAM GROUP P.L.C. (GB) 1989-03-14 US disclosed
EP-0087953-B1 ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS BEECHAM GROUP PLC (GB) 1988-04-27 EP disclosed
EP-0087953-A2 Antibacterial 1-normon-2-yl-heterocyclic compounds BEECHAM GROUP PLC (GB) 1983-09-07 EP disclosed
US-4014876-A HYPOGLYCEMIC SHIONOGI & CO., LTD. (JA) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 MEN1 4467/4885KMT2A 3767/4885ALDH1A1 308/4885
US-11958854-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 MEN1 2331/4885KMT2A 4201/4885ALDH1A1 1647/4885
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 MEN1 2331/4885KMT2A 4201/4885ALDH1A1 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.